Therefore, the predictive value of biomarkers such as CD4+, CD8+, PD-L1, and TMB for PFS and OS in patients with NSCLC receiving anti-PD-1 antibodies was limited. This evidence concerns the gene CD274 and non-small cell lung carcinoma.